Longwood Fund, a Boston, MA-based venture capital firm dedicated to creating and investing in science-based companies, closed its sixth fund, at $180M.
This fund will continue focusing on investing in Longwood-founded companies as well as early financing rounds brought to them by their network of top-tier syndicate partners. The firm will continue working with leading academic researchers and entrepreneurs on technology to create life science companies that will develop the next generation of drugs for patients.
Led by General Partners Christoph Westphal and David Steinberg, Longwood Fund is a venture capital firm dedicated to creating and investing in novel healthcare companies that develop novel solutions to treat important unmet medical needs.
Now with more than $650M in assets under management, Longwood Fund is comprised of partners who have co-founded 24 companies with more than 20 launched or marketed products, with an additional two dozen assets in clinical trials.
FinSMEs
05/05/2023